JP2013537898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537898A5 JP2013537898A5 JP2013529673A JP2013529673A JP2013537898A5 JP 2013537898 A5 JP2013537898 A5 JP 2013537898A5 JP 2013529673 A JP2013529673 A JP 2013529673A JP 2013529673 A JP2013529673 A JP 2013529673A JP 2013537898 A5 JP2013537898 A5 JP 2013537898A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- methylpiperidin
- yloxy
- benzimidazol
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, amino Chemical group 0.000 claims 515
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 243
- 150000001412 amines Chemical class 0.000 claims 76
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 71
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 67
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000004190 benzothiazol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N=C(*)SC2=C1[H] 0.000 claims 24
- IOJUPLGTWVMSFF-UHFFFAOYSA-N cyclobenzothiazole Natural products C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000001475 halogen functional group Chemical group 0.000 claims 13
- 125000004414 alkyl thio group Chemical group 0.000 claims 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 9
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 7
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000004663 dialkyl amino group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 125000004442 acylamino group Chemical group 0.000 claims 3
- 125000004423 acyloxy group Chemical group 0.000 claims 3
- 125000003302 alkenyloxy group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000005122 aminoalkylamino group Chemical group 0.000 claims 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 150000001540 azides Chemical class 0.000 claims 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims 3
- 125000004966 cyanoalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 150000004677 hydrates Chemical class 0.000 claims 3
- 125000005113 hydroxyalkoxy group Chemical group 0.000 claims 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004791 2-fluoroethoxy group Chemical group FCCO* 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 claims 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 claims 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000005096 aminoalkylaminocarbonyl group Chemical group 0.000 claims 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 2
- 150000002989 phenols Chemical class 0.000 claims 2
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 229940075420 xanthine Drugs 0.000 claims 2
- OSRUGVAWNJQIOT-UHFFFAOYSA-N 1-[3-[1,3-benzothiazol-2-yl-(1-methylpiperidin-4-yl)oxymethyl]phenyl]pyrrolidin-3-one dihydrochloride Chemical compound Cl.Cl.CN1CCC(CC1)OC(C1=NC2=CC=CC=C2S1)C1=CC=CC(=C1)N1CCC(=O)C1 OSRUGVAWNJQIOT-UHFFFAOYSA-N 0.000 claims 1
- PDNHLCRMUIGNBV-UHFFFAOYSA-N 1-pyridin-2-ylethanamine Chemical compound CC(N)C1=CC=CC=N1 PDNHLCRMUIGNBV-UHFFFAOYSA-N 0.000 claims 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims 1
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 claims 1
- KJSWRLHLUPFZAD-UHFFFAOYSA-N 2-[(1-methylpiperidin-4-yl)oxy-[3-(trifluoromethylsulfanyl)phenyl]methyl]-1H-benzimidazole oxalic acid Chemical compound CN1CCC(CC1)OC(C1=NC2=C(N1)C=CC=C2)C2=CC(=CC=C2)SC(F)(F)F.C(C(=O)O)(=O)O KJSWRLHLUPFZAD-UHFFFAOYSA-N 0.000 claims 1
- WLLJCHGIPDMWPP-UHFFFAOYSA-N 2-[(1-methylpiperidin-4-yl)oxy-thiophen-2-ylmethyl]-1h-benzimidazole Chemical compound C1CN(C)CCC1OC(C=1NC2=CC=CC=C2N=1)C1=CC=CS1 WLLJCHGIPDMWPP-UHFFFAOYSA-N 0.000 claims 1
- IERXMFRSUIPJFP-UHFFFAOYSA-N 2-[(2,6-difluoro-4-methylphenyl)-(1-methylpiperidin-4-yl)oxymethyl]-1,3-benzoxazole 2-[(3-ethoxy-2,6-difluorophenyl)-(1-methylpiperidin-4-yl)oxymethyl]-1H-benzimidazole oxalic acid Chemical compound FC1=C(C(=CC(=C1)C)F)C(C=1OC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C)OC=2C(=C(C(=CC2)F)C(C2=NC1=C(N2)C=CC=C1)OC1CCN(CC1)C)F.C(C(=O)O)(=O)O IERXMFRSUIPJFP-UHFFFAOYSA-N 0.000 claims 1
- VLOPLJQJEGQLBO-UHFFFAOYSA-N 2-[(2,6-difluoro-4-methylphenyl)-(1-methylpiperidin-4-yl)oxymethyl]-1H-benzimidazole oxalic acid Chemical compound FC1=C(C(=CC(=C1)C)F)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O VLOPLJQJEGQLBO-UHFFFAOYSA-N 0.000 claims 1
- KNMXRHHEUBGBAE-UHFFFAOYSA-N 2-[(3-bromophenyl)-[(1-methylpyrrolidin-3-yl)methoxy]methyl]-6-fluoro-1H-benzimidazole oxalic acid Chemical compound BrC=1C=C(C=CC1)C(C1=NC2=C(N1)C=CC(=C2)F)OCC2CN(CC2)C.C(C(=O)O)(=O)O KNMXRHHEUBGBAE-UHFFFAOYSA-N 0.000 claims 1
- MIOWLTJHTLRQGH-UHFFFAOYSA-N 2-[1-benzothiophen-6-yl-(1-methylpiperidin-4-yl)oxymethyl]-1h-benzimidazole;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1OC(C=1C=C2SC=CC2=CC=1)C1=NC2=CC=CC=C2N1 MIOWLTJHTLRQGH-UHFFFAOYSA-N 0.000 claims 1
- MEXRXWKQEHPMCF-UHFFFAOYSA-N 2-[[2-fluoro-5-(2-fluoroethoxy)phenyl]-(1-methylpiperidin-4-yl)oxymethyl]-1H-benzimidazole oxalic acid Chemical compound FC1=C(C=C(C=C1)OCCF)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O MEXRXWKQEHPMCF-UHFFFAOYSA-N 0.000 claims 1
- OLCJZDALJASXDU-UHFFFAOYSA-N 2-[[2-fluoro-5-(trifluoromethoxy)phenyl]-(1-methylpiperidin-4-yl)oxymethyl]-1,3-benzothiazole oxalic acid Chemical compound FC1=C(C=C(C=C1)OC(F)(F)F)C(C=1SC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O OLCJZDALJASXDU-UHFFFAOYSA-N 0.000 claims 1
- IJBUNLUGCLPARD-UHFFFAOYSA-N 2-[[3,5-bis(trifluoromethyl)phenyl]-(1-methylpiperidin-4-yl)oxymethyl]-1H-benzimidazole oxalic acid Chemical compound FC(C=1C=C(C=C(C1)C(F)(F)F)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C)(F)F.C(C(=O)O)(=O)O IJBUNLUGCLPARD-UHFFFAOYSA-N 0.000 claims 1
- KXHDPASARHXTSO-UHFFFAOYSA-N 2-[[3-(3-fluoropyrrolidin-1-yl)phenyl]-(1-methylpiperidin-4-yl)oxymethyl]-1,3-benzothiazole oxalic acid Chemical compound FC1CN(CC1)C=1C=C(C=CC1)C(C=1SC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O KXHDPASARHXTSO-UHFFFAOYSA-N 0.000 claims 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000001331 3-methylbutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
- JYLOICJEZROGMN-UHFFFAOYSA-N 4-[1H-benzimidazol-2-yl-(1-methylpiperidin-4-yl)oxymethyl]phenol 2-[[3-(3,3-difluoropyrrolidin-1-yl)phenyl]-(1-methylpiperidin-4-yl)oxymethyl]-1H-benzimidazole oxalic acid Chemical compound FC1(CN(CC1)C=1C=C(C=CC1)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C)F.N2C(=NC1=C2C=CC=C1)C(C1=CC=C(C=C1)O)OC1CCN(CC1)C.C(C(=O)O)(=O)O JYLOICJEZROGMN-UHFFFAOYSA-N 0.000 claims 1
- PBZHPSHIZGZTAC-UHFFFAOYSA-N 4-[3-[(1-methylpiperidin-4-yl)oxy-(4,5,6-trifluoro-1H-benzimidazol-2-yl)methyl]phenyl]sulfanylbutan-1-amine oxalic acid Chemical compound CN1CCC(CC1)OC(C=1C=C(C=CC1)SCCCCN)C1=NC2=C(N1)C(=C(C(=C2)F)F)F.C(C(=O)O)(=O)O PBZHPSHIZGZTAC-UHFFFAOYSA-N 0.000 claims 1
- AVIPAJNDABZYBC-UHFFFAOYSA-N 4-[3-[1,3-benzothiazol-2-yl-(1-methylpiperidin-4-yl)oxymethyl]phenoxy]cyclohexan-1-amine oxalic acid Chemical compound S1C(=NC2=C1C=CC=C2)C(C=2C=C(OC1CCC(CC1)N)C=CC2)OC2CCN(CC2)C.C(C(=O)O)(=O)O AVIPAJNDABZYBC-UHFFFAOYSA-N 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000000439 4-methylpentoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims 1
- BKAWJIRCKVUVED-UHFFFAOYSA-N 5-(2-hydroxyethyl)-4-methylthiazole Chemical compound CC=1N=CSC=1CCO BKAWJIRCKVUVED-UHFFFAOYSA-N 0.000 claims 1
- 102000004023 5-Lipoxygenase-Activating Proteins Human genes 0.000 claims 1
- 108090000411 5-Lipoxygenase-Activating Proteins Proteins 0.000 claims 1
- FLVIVBHVEZYHAM-UHFFFAOYSA-N 5-[3-[(6-fluoro-1H-benzimidazol-2-yl)-[(1-methylpyrrolidin-3-yl)methoxy]methyl]phenyl]pent-4-yn-1-amine oxalic acid Chemical compound FC1=CC2=C(NC(=N2)C(C=2C=C(C=CC2)C#CCCCN)OCC2CN(CC2)C)C=C1.C(C(=O)O)(=O)O FLVIVBHVEZYHAM-UHFFFAOYSA-N 0.000 claims 1
- CQKMWMWZINHTLF-UHFFFAOYSA-N 5-[3-[1H-benzimidazol-2-yl-(1-methylpiperidin-4-yl)oxymethyl]phenyl]sulfanylpentan-1-ol dihydrochloride Chemical compound CN1CCC(CC1)OC(C2=CC(=CC=C2)SCCCCCO)C3=NC4=CC=CC=C4N3.Cl.Cl CQKMWMWZINHTLF-UHFFFAOYSA-N 0.000 claims 1
- IJFQDYLZCRTTBD-UHFFFAOYSA-N 5-[[3-[1H-benzimidazol-2-yl-(1-methylpiperidin-4-yl)oxymethyl]phenyl]sulfanylmethyl]-1,3-oxazolidin-2-one oxalic acid Chemical compound N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)SCC2CNC(O2)=O)OC2CCN(CC2)C.C(C(=O)O)(=O)O IJFQDYLZCRTTBD-UHFFFAOYSA-N 0.000 claims 1
- BWUJPQLWIVZJMK-UHFFFAOYSA-N 6-[3-[(1-ethylbenzimidazol-2-yl)-(1-methylpiperidin-4-yl)oxymethyl]phenyl]hex-5-yn-1-amine;oxalic acid Chemical compound OC(=O)C(O)=O.N=1C2=CC=CC=C2N(CC)C=1C(C=1C=C(C=CC=1)C#CCCCCN)OC1CCN(C)CC1 BWUJPQLWIVZJMK-UHFFFAOYSA-N 0.000 claims 1
- IGCGOFYHIYXCBB-UHFFFAOYSA-N 6-[3-[(1-methylbenzimidazol-2-yl)-(1-methylpiperidin-4-yl)oxymethyl]phenyl]hex-5-yn-1-amine oxalic acid Chemical compound CN1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)C#CCCCCN)OC2CCN(CC2)C.C(C(=O)O)(=O)O IGCGOFYHIYXCBB-UHFFFAOYSA-N 0.000 claims 1
- ICULYQJITXDWET-UHFFFAOYSA-N 6-[3-[[1-(2-ethoxyethyl)benzimidazol-2-yl]-(1-methylpiperidin-4-yl)oxymethyl]phenyl]hex-5-yn-1-amine oxalic acid Chemical compound C(C)OCCN1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)C#CCCCCN)OC2CCN(CC2)C.C(C(=O)O)(=O)O ICULYQJITXDWET-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- DXQNUBLYTPJHBB-UHFFFAOYSA-N BrC=1C=C(C=CC1)C(C=1SC2=C(N1)C=CC=C2)OCC2CN(CC2)C.C(C(=O)O)(=O)O Chemical compound BrC=1C=C(C=CC1)C(C=1SC2=C(N1)C=CC=C2)OCC2CN(CC2)C.C(C(=O)O)(=O)O DXQNUBLYTPJHBB-UHFFFAOYSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- MJJZBVNPBPXOLW-UHFFFAOYSA-N C(C)(=O)NSC1=CC(=CC=C1)C(OC1CCN(CC1)C)C1=NC2=C(N1)C=CC=C2 Chemical compound C(C)(=O)NSC1=CC(=CC=C1)C(OC1CCN(CC1)C)C1=NC2=C(N1)C=CC=C2 MJJZBVNPBPXOLW-UHFFFAOYSA-N 0.000 claims 1
- BYGWAUNJYVQHOH-UHFFFAOYSA-N C(C)SC=1C(=C(C(=CC1)F)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C)F.C(C(=O)O)(=O)O Chemical compound C(C)SC=1C(=C(C(=CC1)F)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C)F.C(C(=O)O)(=O)O BYGWAUNJYVQHOH-UHFFFAOYSA-N 0.000 claims 1
- SYFMPENOKMUXFI-UHFFFAOYSA-N CN1CCC(CC1)OC(C1=NC2=C(N1)C=CC=C2)C2=CC(=CC=C2)OC2CNCC2.C(C(=O)O)(=O)O Chemical compound CN1CCC(CC1)OC(C1=NC2=C(N1)C=CC=C2)C2=CC(=CC=C2)OC2CNCC2.C(C(=O)O)(=O)O SYFMPENOKMUXFI-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical group C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 208000017667 Chronic Disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- RUENINABXSWAOC-UHFFFAOYSA-N ClC1=CC(=C(C(=C1)F)C(C=1SC2=C(N1)C=CC=C2)OC2CCN(CC2)C)F.C(C(=O)O)(=O)O Chemical compound ClC1=CC(=C(C(=C1)F)C(C=1SC2=C(N1)C=CC=C2)OC2CCN(CC2)C)F.C(C(=O)O)(=O)O RUENINABXSWAOC-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- NROXOIIUJVGYNV-UHFFFAOYSA-N FC1=C(C(=CC(=C1)C)F)C(C=1SC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C(=CC(=C1)C)F)C(C=1SC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O NROXOIIUJVGYNV-UHFFFAOYSA-N 0.000 claims 1
- NURJGTORLADJER-UHFFFAOYSA-N FC1=C(C=C(C=C1)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C)OC(F)(F)F.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C)OC(F)(F)F.C(C(=O)O)(=O)O NURJGTORLADJER-UHFFFAOYSA-N 0.000 claims 1
- RKDOIUWHOMSPIZ-UHFFFAOYSA-N FC1=C(C=C(C=C1)C(F)(F)F)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)C(F)(F)F)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O RKDOIUWHOMSPIZ-UHFFFAOYSA-N 0.000 claims 1
- PNMOESXIRZGBBS-UHFFFAOYSA-N FC1=C(C=C(C=C1)C)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)C)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O PNMOESXIRZGBBS-UHFFFAOYSA-N 0.000 claims 1
- QMQLGQZQUPRZCA-UHFFFAOYSA-N FC1=C(C=C(C=C1)OC(F)(F)F)C(C1=NC2=C(N1)C=CC=C2)OCC2CN(C2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)OC(F)(F)F)C(C1=NC2=C(N1)C=CC=C2)OCC2CN(C2)C.C(C(=O)O)(=O)O QMQLGQZQUPRZCA-UHFFFAOYSA-N 0.000 claims 1
- BSKCXIYPBXWSSK-UHFFFAOYSA-N FC1=C(C=C(C=C1)OC(F)(F)F)C(C=1OC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)OC(F)(F)F)C(C=1OC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O BSKCXIYPBXWSSK-UHFFFAOYSA-N 0.000 claims 1
- NGFAEWSPSSTIHM-UHFFFAOYSA-N FC1=C(C=C(C=C1)OC)C(C1=NC2=C(N1)C=CC=C2)OCC2CN(CC2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)OC)C(C1=NC2=C(N1)C=CC=C2)OCC2CN(CC2)C.C(C(=O)O)(=O)O NGFAEWSPSSTIHM-UHFFFAOYSA-N 0.000 claims 1
- WXZKGZXGVYFONT-UHFFFAOYSA-N FC1=C(C=C(C=C1)OCCC)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound FC1=C(C=C(C=C1)OCCC)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O WXZKGZXGVYFONT-UHFFFAOYSA-N 0.000 claims 1
- XQZZTJNSTAWVSV-UHFFFAOYSA-N FC1=C(C=CC(=C1)C)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.COC(CC2=CC(=CC=C2)Br)=O Chemical compound FC1=C(C=CC(=C1)C)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.COC(CC2=CC(=CC=C2)Br)=O XQZZTJNSTAWVSV-UHFFFAOYSA-N 0.000 claims 1
- PSUNCCMTEACKBB-UHFFFAOYSA-N FC1=CC2=C(NC(=N2)C(C=2C=C(C=CC2)SCCCCN)OC2CCN(CC2)C)C=C1F.C(C(=O)O)(=O)O Chemical compound FC1=CC2=C(NC(=N2)C(C=2C=C(C=CC2)SCCCCN)OC2CCN(CC2)C)C=C1F.C(C(=O)O)(=O)O PSUNCCMTEACKBB-UHFFFAOYSA-N 0.000 claims 1
- URXLEBLSZBRAFC-UHFFFAOYSA-N FCCOC=1C=C(C=CC1)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound FCCOC=1C=C(C=CC1)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O URXLEBLSZBRAFC-UHFFFAOYSA-N 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000023783 Genitourinary tract disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims 1
- 208000018501 Lymphatic disease Diseases 0.000 claims 1
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-butylamine Natural products CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- DLLJQNCMRBNUJV-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)C(C2=CC=C(N)C=C2)OC2CCNCC2.N2C(=NC1=C2C=CC=C1)C(C1=CC=C(N)C=C1)OC1CCN(CC1)C.C(C(=O)O)(=O)O Chemical compound N1C(=NC2=C1C=CC=C2)C(C2=CC=C(N)C=C2)OC2CCNCC2.N2C(=NC1=C2C=CC=C1)C(C1=CC=C(N)C=C1)OC1CCN(CC1)C.C(C(=O)O)(=O)O DLLJQNCMRBNUJV-UHFFFAOYSA-N 0.000 claims 1
- NJAIUXLHAWKVKF-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)N2CC(CC2)O)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)N2CC(CC2)O)OC2CCN(CC2)C.C(C(=O)O)(=O)O NJAIUXLHAWKVKF-UHFFFAOYSA-N 0.000 claims 1
- FYDZTEMUZKWOCI-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)SCCCCNC(=N)N)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)SCCCCNC(=N)N)OC2CCN(CC2)C.C(C(=O)O)(=O)O FYDZTEMUZKWOCI-UHFFFAOYSA-N 0.000 claims 1
- GIZPWVUPZVGHKY-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)SCCN(C(=N)N)C(C(C)C)=O)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2)SCCN(C(=N)N)C(C(C)C)=O)OC2CCN(CC2)C.C(C(=O)O)(=O)O GIZPWVUPZVGHKY-UHFFFAOYSA-N 0.000 claims 1
- NYDWMVGNKAFKIB-UHFFFAOYSA-N N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2F)O)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound N1C(=NC2=C1C=CC=C2)C(C=2C=C(C=CC2F)O)OC2CCN(CC2)C.C(C(=O)O)(=O)O NYDWMVGNKAFKIB-UHFFFAOYSA-N 0.000 claims 1
- CODMSXJCTVEFCK-UHFFFAOYSA-N N1C=CC2=CC=C(C=C12)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O Chemical compound N1C=CC2=CC=C(C=C12)C(C1=NC2=C(N1)C=CC=C2)OC2CCN(CC2)C.C(C(=O)O)(=O)O CODMSXJCTVEFCK-UHFFFAOYSA-N 0.000 claims 1
- 206010028735 Nasal congestion Diseases 0.000 claims 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000001435 Thromboembolism Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010064948 Viral rhinitis Diseases 0.000 claims 1
- OAZYHDBQWBHPBV-UHFFFAOYSA-N [3-[1h-benzimidazol-2-yl-(1-methylpiperidin-4-yl)oxymethyl]phenyl]methanol;oxalic acid Chemical compound OC(=O)C(O)=O.C1CN(C)CCC1OC(C=1C=C(CO)C=CC=1)C1=NC2=CC=CC=C2N1 OAZYHDBQWBHPBV-UHFFFAOYSA-N 0.000 claims 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 230000008369 airway response Effects 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 230000002009 allergenic effect Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N allylamine Natural products NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims 1
- 229960003556 aminophylline Drugs 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- MJABXZWILYUAEB-UHFFFAOYSA-N benzimidazole-1-carboxylic acid Chemical compound C1=CC=C2N(C(=O)O)C=NC2=C1 MJABXZWILYUAEB-UHFFFAOYSA-N 0.000 claims 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims 1
- 229960002071 bepotastine Drugs 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229960001271 desloratadine Drugs 0.000 claims 1
- AHCDMQLWEBVOTN-UHFFFAOYSA-N diethyl-[6-[(6-methoxy-1,3-benzothiazol-4-yl)amino]hexyl]azanium;2-hydroxy-2-oxoacetate Chemical compound OC(=O)C([O-])=O.CC[NH+](CC)CCCCCCNC1=CC(OC)=CC2=C1N=CS2 AHCDMQLWEBVOTN-UHFFFAOYSA-N 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims 1
- 229960005426 doxepin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- WCASXYBKJHWFMY-UHFFFAOYSA-N gamma-methylallyl alcohol Natural products CC=CCO WCASXYBKJHWFMY-UHFFFAOYSA-N 0.000 claims 1
- 125000005241 heteroarylamino group Chemical group 0.000 claims 1
- 229960001340 histamine Drugs 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 108091006086 inhibitor proteins Proteins 0.000 claims 1
- 229960004958 ketotifen Drugs 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 201000005857 malignant hypertension Diseases 0.000 claims 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N monoethyl amine Natural products CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229960002259 nedocromil sodium Drugs 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 125000002524 organometallic group Chemical group 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000005592 polycycloalkyl group Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229940127230 sympathomimetic drug Drugs 0.000 claims 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20100306038 EP2447263A1 (en) | 2010-09-27 | 2010-09-27 | Benzazole derivatives as histamine H4 receptor ligands |
| EP10306038.0 | 2010-09-27 | ||
| PCT/EP2011/066782 WO2012041860A1 (en) | 2010-09-27 | 2011-09-27 | Benzazole derivatives as histamine h4 receptor ligands |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537898A JP2013537898A (ja) | 2013-10-07 |
| JP2013537898A5 true JP2013537898A5 (enExample) | 2016-04-14 |
| JP5922128B2 JP5922128B2 (ja) | 2016-05-24 |
Family
ID=43513798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529673A Active JP5922128B2 (ja) | 2010-09-27 | 2011-09-27 | ヒスタミンｈ４受容体リガンドとしてのベンザゾール誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8802664B2 (enExample) |
| EP (2) | EP2447263A1 (enExample) |
| JP (1) | JP5922128B2 (enExample) |
| CN (1) | CN103228643B (enExample) |
| CA (1) | CA2812686C (enExample) |
| CY (1) | CY1117416T1 (enExample) |
| DK (1) | DK2621916T3 (enExample) |
| ES (1) | ES2571335T3 (enExample) |
| HR (1) | HRP20160398T1 (enExample) |
| HU (1) | HUE027252T2 (enExample) |
| MX (1) | MX339460B (enExample) |
| PL (1) | PL2621916T3 (enExample) |
| RS (1) | RS54737B1 (enExample) |
| SI (1) | SI2621916T1 (enExample) |
| SM (1) | SMT201600262B (enExample) |
| WO (1) | WO2012041860A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2699344A1 (en) | 2011-04-19 | 2014-02-26 | Saudi Basic Industries Corporation | Carbon supported cobalt and molybdenum catalyst |
| SG11201406973PA (en) * | 2012-05-04 | 2014-12-30 | Novartis Ag | Complement pathway modulators and uses thereof |
| EP2671870A1 (en) | 2012-06-05 | 2013-12-11 | Bioprojet | Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications |
| HUE039713T2 (hu) | 2012-06-08 | 2019-02-28 | Sensorion | H4 receptor inhibitorok tinnitus kezelésére |
| CN104710341A (zh) * | 2015-02-13 | 2015-06-17 | 佛山市赛维斯医药科技有限公司 | 一类含双酰肼和萘基结构的化合物、制备方法及其用途 |
| JP7447002B2 (ja) * | 2017-09-11 | 2024-03-11 | クルーゾン・ファーマシューティカルズ・インコーポレイテッド | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 |
| US11306069B2 (en) * | 2017-11-15 | 2022-04-19 | Bioprojet | Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands |
| CN113278409B (zh) * | 2021-06-22 | 2022-04-29 | 西南石油大学 | 一种高温酸化缓蚀剂 |
| CN119086786B (zh) * | 2024-11-08 | 2025-02-14 | 南京恒远科技开发有限公司 | 叔丁基-(s)-[2-(2-氰基-4,4-二氟吡咯烷-1-基)-2-氧乙基]氨基甲酸酯光学异构体的检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI803127L (fi) * | 1979-10-03 | 1981-04-04 | Glaxo Group Ltd | Heterocykliska foereningar |
| IT1154888B (it) * | 1980-11-12 | 1987-01-21 | Menarini Sas | Derivati del benzofurano 2-sostituiti e relativi metodi di preparazione |
| US4908372A (en) * | 1988-10-13 | 1990-03-13 | Merrell Dow Pharmaceuticals Inc. | Antihistaminic piperidinyl benzimidazoles |
| JPH05339266A (ja) * | 1992-06-05 | 1993-12-21 | Kaken Pharmaceut Co Ltd | 新規なピペリジン誘導体 |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| CA2467718C (en) | 2001-12-21 | 2011-04-26 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| US20060127404A1 (en) * | 2003-09-30 | 2006-06-15 | Chichi Huang | Hinge core mimetibodies, compositions, methods and uses |
| AR045955A1 (es) * | 2003-09-30 | 2005-11-16 | Janssen Pharmaceutica Nv | Compuestos benzoimidazolicos |
| EP1642577A1 (en) * | 2004-09-07 | 2006-04-05 | Laboratorios del Dr. Esteve S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of central neuropathic pain |
| US7557103B2 (en) | 2005-04-05 | 2009-07-07 | Eli Lilly And Company | Imidazopyridazine compounds |
| WO2009089057A1 (en) | 2008-01-09 | 2009-07-16 | Renovis, Ins. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
-
2010
- 2010-09-27 EP EP20100306038 patent/EP2447263A1/en not_active Withdrawn
-
2011
- 2011-09-27 HU HUE11761383A patent/HUE027252T2/en unknown
- 2011-09-27 PL PL11761383T patent/PL2621916T3/pl unknown
- 2011-09-27 US US13/825,989 patent/US8802664B2/en active Active
- 2011-09-27 EP EP11761383.6A patent/EP2621916B1/en active Active
- 2011-09-27 RS RS20160297A patent/RS54737B1/sr unknown
- 2011-09-27 CN CN201180057036.8A patent/CN103228643B/zh active Active
- 2011-09-27 ES ES11761383T patent/ES2571335T3/es active Active
- 2011-09-27 MX MX2013003479A patent/MX339460B/es active IP Right Grant
- 2011-09-27 HR HRP20160398TT patent/HRP20160398T1/hr unknown
- 2011-09-27 CA CA2812686A patent/CA2812686C/en active Active
- 2011-09-27 DK DK11761383.6T patent/DK2621916T3/en active
- 2011-09-27 JP JP2013529673A patent/JP5922128B2/ja active Active
- 2011-09-27 WO PCT/EP2011/066782 patent/WO2012041860A1/en not_active Ceased
- 2011-09-27 SI SI201130817A patent/SI2621916T1/sl unknown
-
2014
- 2014-06-27 US US14/317,024 patent/US9029357B2/en active Active
-
2016
- 2016-04-26 CY CY20161100339T patent/CY1117416T1/el unknown
- 2016-08-03 SM SM201600262T patent/SMT201600262B/it unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160398T1 (hr) | Derivati benzazola kao ligandi receptora histamina h4 | |
| RU2469032C2 (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы | |
| RU2373209C2 (ru) | Пирролотриазиновые соединения как ингибиторы киназ | |
| US7148258B2 (en) | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | |
| RU2436776C2 (ru) | ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT | |
| RU2004112770A (ru) | Производные имидазол-4-карбоксамида, их получение и применение для лечения ожирения | |
| JP2010523674A5 (enExample) | ||
| RU2003129502A (ru) | Соединение, фармацевтическая композиция, применение, способ предупреждения или лечения заболеваний | |
| RU2003118448A (ru) | Производные замещенного триазолдиамина и их применение в качестве ингибиторов киназы | |
| RU2010142937A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ | |
| EA005924B1 (ru) | Ассоциация или комбинация антагониста рецептора cb1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
| RU2004122407A (ru) | Амидные производные в качестве активаторов gk | |
| ZA200205551B (en) | Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors. | |
| RU2011115111A (ru) | Замещенные пирролидин-2-карбоксамиды | |
| JP2012505881A5 (enExample) | ||
| RU2007130532A (ru) | Дизамещенные мочевины в качестве ингибиторов киназы | |
| RU2005111589A (ru) | Производные 1-пиридин-4-илмочевины | |
| JP2006522820A5 (enExample) | ||
| RU2019117958A (ru) | Производные индола, полезные в качестве ингибиторов диацилглицерид-о-ацилтрансферазы 2 | |
| IL171894A (en) | Aztidine compounds, preparations and pharmaceutical preparations containing them | |
| RU2006113948A (ru) | Производные пиридина и их применение в качестве антагонистов уротензина ii | |
| RU2006134022A (ru) | Производные индазола и содержащие их фармацевтические композиции | |
| CN1531433A (zh) | 一种用于预防或治疗糖尿病的协同药物组合物 | |
| RU2012131276A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина | |
| RU2015114937A (ru) | Замещенные соединения карбамата и их применение в качестве антагонистов канала с транзиторным рецепторным потенциалом (trp) |